Do analysts rate TMDIF or CVRX?

CVRx has a consensus target price of $6.90, suggesting a potential upside of 124.03%. Given CVRx's stronger consensus rating and higher possible upside, analysts clearly believe CVRx is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CVRx 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, TMDIF or CVRX?

Titan Medical has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.95 $6.95M $0.05 2.93 CVRx $56.65M 1.45 -$53.31M -$1.98 N/A

Is TMDIF or CVRX more profitable?

Titan Medical has a net margin of 0.00% compared to CVRx's net margin of -84.93%. Titan Medical's return on equity of -82.31% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% CVRx -84.93% -152.35% -50.93%

Do analysts rate TMDIF or NYXH?

Nyxoah has a consensus price target of $5.26, indicating a potential upside of 224.81%. Given Nyxoah's stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, TMDIF or NYXH?

Titan Medical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.95 $6.95M $0.05 2.93 Nyxoah $11.33M 5.54 -$101.92M -$2.52 N/A

Is TMDIF or NYXH more profitable?

Titan Medical has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Titan Medical's return on equity of -82.31% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Nyxoah -443.16% -178.90% -81.83%

Do analysts rate TMDIF or DXR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, TMDIF or DXR?

Titan Medical has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Titan Medical $17.63M 0.95 $6.95M $0.05 2.93 Daxor N/A N/A N/A N/A N/A

Is TMDIF or DXR more profitable?

Daxor's return on equity of 0.00% beat Titan Medical's return on equity. Company Net Margins Return on Equity Return on Assets Titan Medical N/A -82.31% -51.47% Daxor N/A N/A N/A

Do analysts prefer MDAI or TMDIF?

Spectral AI currently has a consensus price target of $4.00, indicating a potential upside of 138.10%. Given Spectral AI's stronger consensus rating and higher possible upside, equities research analysts plainly believe Spectral AI is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spectral AI 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate COCH or TMDIF?

Envoy Medical currently has a consensus price target of $2.25, indicating a potential upside of 181.25%. Given Envoy Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Envoy Medical is more favorable than Titan Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Envoy Medical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Titan Medical (TMDIF) Competitors

$0.15 +0.01 (+4.49%)

As of 08/13/2026

Compare

TMDIF vs. CVRX, NYXH, DXR, MDAI, and COCH

Should you buy Titan Medical stock or one of its competitors? Titan Medical's main competitors and comparable companies include CVRx (CVRX), Nyxoah (NYXH), Daxor (DXR), Spectral AI (MDAI), and Envoy Medical (COCH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Titan Medical compare to CVRx?

Titan Medical (NASDAQ:TMDIF) and CVRx (NASDAQ:CVRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Titan Medical has a net margin of 0.00% compared to CVRx's net margin of -84.93%. Titan Medical's return on equity of -82.31% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
CVRx	-84.93%	-152.35%	-50.93%

CVRx has a consensus target price of $6.90, suggesting a potential upside of 124.03%. Given CVRx's stronger consensus rating and higher possible upside, analysts clearly believe CVRx is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CVRx	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, CVRx had 19 more articles in the media than Titan Medical. MarketBeat recorded 19 mentions for CVRx and 0 mentions for Titan Medical. CVRx's average media sentiment score of 0.02 beat Titan Medical's score of 0.00 indicating that CVRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
CVRx	Neutral

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 75.3% of CVRx shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 16.6% of CVRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, CVRx has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Titan Medical has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.95	$6.95M	$0.05	2.93
CVRx	$56.65M	1.45	-$53.31M	-$1.98	N/A

Summary

CVRx beats Titan Medical on 11 of the 17 factors compared between the two stocks.

How does Titan Medical compare to Nyxoah?

Titan Medical (NASDAQ:TMDIF) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Nyxoah had 3 more articles in the media than Titan Medical. MarketBeat recorded 3 mentions for Nyxoah and 0 mentions for Titan Medical. Nyxoah's average media sentiment score of 0.64 beat Titan Medical's score of 0.00 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Nyxoah	Positive

Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

Nyxoah has a consensus price target of $5.26, indicating a potential upside of 224.81%. Given Nyxoah's stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Titan Medical has a net margin of 0.00% compared to Nyxoah's net margin of -443.16%. Titan Medical's return on equity of -82.31% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Nyxoah	-443.16%	-178.90%	-81.83%

0.0% of Titan Medical shares are owned by institutional investors. 0.0% of Titan Medical shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Titan Medical has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.95	$6.95M	$0.05	2.93
Nyxoah	$11.33M	5.54	-$101.92M	-$2.52	N/A

Summary

Titan Medical and Nyxoah tied by winning 8 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Daxor?

Titan Medical (NASDAQ:TMDIF) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Titan Medical has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Medical	$17.63M	0.95	$6.95M	$0.05	2.93
Daxor	N/A	N/A	N/A	N/A	N/A

Titan Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Titan Medical	N/A	-82.31%	-51.47%
Daxor	N/A	N/A	N/A

0.0% of Titan Medical shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 0.0% of Titan Medical shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Daxor had 4 more articles in the media than Titan Medical. MarketBeat recorded 4 mentions for Daxor and 0 mentions for Titan Medical. Daxor's average media sentiment score of 1.20 beat Titan Medical's score of 0.00 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
Titan Medical	Neutral
Daxor	Positive

Summary

Daxor beats Titan Medical on 8 of the 10 factors compared between the two stocks.

How does Titan Medical compare to Spectral AI?

Spectral AI (NASDAQ:MDAI) and Titan Medical (NASDAQ:TMDIF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Spectral AI currently has a consensus price target of $4.00, indicating a potential upside of 138.10%. Given Spectral AI's stronger consensus rating and higher possible upside, equities research analysts plainly believe Spectral AI is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Spectral AI has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

In the previous week, Spectral AI had 13 more articles in the media than Titan Medical. MarketBeat recorded 13 mentions for Spectral AI and 0 mentions for Titan Medical. Spectral AI's average media sentiment score of 0.60 beat Titan Medical's score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.

Company	Overall Sentiment
Spectral AI	Positive
Titan Medical	Neutral

Titan Medical has lower revenue, but higher earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.72	-$7.57M	-$0.53	N/A
Titan Medical	$17.63M	0.95	$6.95M	$0.05	2.93

67.1% of Spectral AI shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 13.7% of Spectral AI shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Titan Medical has a net margin of 0.00% compared to Spectral AI's net margin of -69.27%. Spectral AI's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-69.27%	N/A	-78.56%
Titan Medical	N/A	-82.31%	-51.47%

Summary

Spectral AI beats Titan Medical on 11 of the 16 factors compared between the two stocks.

How does Titan Medical compare to Envoy Medical?

Envoy Medical (NASDAQ:COCH) and Titan Medical (NASDAQ:TMDIF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Envoy Medical has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Titan Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat Titan Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-11,304.83%	N/A	-144.13%
Titan Medical	N/A	-82.31%	-51.47%

Titan Medical has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240K	257.30	-$23.76M	-$0.76	N/A
Titan Medical	$17.63M	0.95	$6.95M	$0.05	2.93

Envoy Medical currently has a consensus price target of $2.25, indicating a potential upside of 181.25%. Given Envoy Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Envoy Medical is more favorable than Titan Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Envoy Medical had 5 more articles in the media than Titan Medical. MarketBeat recorded 5 mentions for Envoy Medical and 0 mentions for Titan Medical. Envoy Medical's average media sentiment score of 0.47 beat Titan Medical's score of 0.00 indicating that Envoy Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Envoy Medical	Neutral
Titan Medical	Neutral

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by insiders. Comparatively, 0.0% of Titan Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Envoy Medical beats Titan Medical on 10 of the 15 factors compared between the two stocks.

Get Titan Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDIF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDIF vs. The Competition

Export

Metric	Titan Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.71M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-0.12	21.85	211.09	21.74
Price / Sales	0.95	63.14	602.98	92.99
Price / Cash	0.02	33.92	70.48	50.90
Price / Book	0.14	6.10	12.91	6.24
Net Income	$6.95M	$148.67M	$3.45B	$347.60M
7 Day Performance	-2.34%	1.84%	1.12%	1.07%
1 Month Performance	-7.54%	4.56%	1.79%	1.03%
1 Year Performance	-60.22%	8.67%	67.69%	20.77%

Titan Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDIF Titan Medical	N/A	$0.15 +4.5%	N/A	-61.9%	$16.71M	$17.63M	N/A	50	Gap Down
CVRX CVRx	3.4288 of 5 stars	$2.29 -4.1%	$6.90 +201.2%	-61.9%	$61.54M	$56.65M	N/A	160	News Coverage Gap Up High Trading Volume
NYXH Nyxoah	3.044 of 5 stars	$1.55 +5.1%	$5.26 +240.6%	-75.0%	$59.88M	$11.33M	N/A	110	Gap Up
DXR Daxor	2.3914 of 5 stars	$10.20 +0.8%	N/A	-5.3%	$59.54M	N/A	N/A	37	News Coverage Positive News Upcoming Earnings Short Interest Decrease
MDAI Spectral AI	3.0975 of 5 stars	$1.74 -0.9%	$4.00 +130.5%	-18.4%	$55.21M	$19.65M	N/A	83	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDIF) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Titan Medical (TMDIF) Competitors

TMDIF vs. CVRX, NYXH, DXR, MDAI, and COCH

How does Titan Medical compare to CVRx?

Summary

How does Titan Medical compare to Nyxoah?

Summary

How does Titan Medical compare to Daxor?

Summary

How does Titan Medical compare to Spectral AI?

Summary

How does Titan Medical compare to Envoy Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Titan Medical (TMDIF) Competitors

TMDIF vs. CVRX, NYXH, DXR, MDAI, and COCH

How does Titan Medical compare to CVRx?

Is TMDIF or CVRX more profitable?

Do analysts rate TMDIF or CVRX?

Does the media favor TMDIF or CVRX?

Do insiders & institutionals have more ownership in TMDIF or CVRX?

Which has more risk and volatility, TMDIF or CVRX?

Which has higher valuation and earnings, TMDIF or CVRX?

Summary

How does Titan Medical compare to Nyxoah?

Does the media favor TMDIF or NYXH?

Which has more risk and volatility, TMDIF or NYXH?

Do analysts rate TMDIF or NYXH?

Is TMDIF or NYXH more profitable?

Do insiders & institutionals believe in TMDIF or NYXH?

Which has stronger earnings & valuation, TMDIF or NYXH?

Summary

How does Titan Medical compare to Daxor?

Which has stronger valuation & earnings, TMDIF or DXR?

Which has more volatility and risk, TMDIF or DXR?

Do analysts rate TMDIF or DXR?

Is TMDIF or DXR more profitable?

Do insiders and institutionals hold more shares of TMDIF or DXR?

Does the media prefer TMDIF or DXR?

Summary

How does Titan Medical compare to Spectral AI?

Do analysts prefer MDAI or TMDIF?

Which has more risk and volatility, MDAI or TMDIF?

Does the media prefer MDAI or TMDIF?

Which has stronger valuation & earnings, MDAI or TMDIF?

Do institutionals & insiders believe in MDAI or TMDIF?

Is MDAI or TMDIF more profitable?

Summary

How does Titan Medical compare to Envoy Medical?

Which has more volatility and risk, COCH or TMDIF?

Is COCH or TMDIF more profitable?

Which has preferable valuation & earnings, COCH or TMDIF?

Do analysts rate COCH or TMDIF?

Does the media refer more to COCH or TMDIF?

Do institutionals and insiders believe in COCH or TMDIF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDIF vs. The Competition

Titan Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools